Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.71 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.68 |
| ▸ | FABP1 | P07148 | 1/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.66 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.64 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.64 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13601054 | 0.98 | NPC1 (0.77) | FFAR1NPC1RAB9ASMN1; SMN2PGR | |
| SCHEMBL8737301 | 0.91 | FFAR1 (0.69) | FFAR1NPC1RAB9ASMN1; SMN2PGR | |
| SCHEMBL9240473 | 0.90 | PGR (0.84) | FFAR1NPC1RAB9ASMN1; SMN2PGR | |
| SCHEMBL22543145 | 0.90 | NR1H4 (0.78) | FFAR1NPC1RAB9APGRMEN1 | |
| SCHEMBL94989 | 0.90 | PGR (0.68) | FFAR1NPC1RAB9ASMN1; SMN2PGR | |
| SCHEMBL27874895 | 0.88 | NPC1 (0.73) | FFAR1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30949335 | 0.86 | PGR (0.87) | NPC1RAB9ASMN1; SMN2PGRMEN1 | |
| SCHEMBL5226157 | 0.85 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2PGRMEN1 | |
| SCHEMBL12189652 | 0.85 | NR1H4 (0.63) | FFAR1NPC1RAB9ASMN1; SMN2PGR | |
| SCHEMBL5694520 | 0.84 | PGR (1.00) | NPC1RAB9ASMN1; SMN2PGRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | CONNOR DAVID THOMAS (US) | 2001-10-18 | — | — | US | claimed |
| EP-1042276-A1 | THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY LLC (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999032433-A1 | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | claimed |
| US-6528528-B2 | Inhibitors of 15-lipoxygenase, inhibiting chemotaxis of monocytes | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | CONNOR DAVID THOMAS (US) | 2001-10-18 | — | — | US | disclosed |
| US-6268387-B1 | INHIBITORS OF THE ENZYME 15-LIPOXYGENASE AND ARE INHIBITORS OF MONOCYTE CHEMOTAXIS. | WARNER-LAMBERT COMPANY | 2001-07-31 | — | — | US | disclosed |
| EP-1042276-A1 | THIOUREA COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY LLC (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032433-A1 | THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING OR PREVENTING INFLAMMATORY DISEASES AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031874-A1 | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis | TPMT, CTH, CBS | FFAR1 495/4885NPC1 230/4885RAB9A 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.